Dr. Judice currently serves as the co-founder and chief executive officer at DiCE Molecules. Prior to DiCE Molecules, Dr. Judice served as chief scientific officer at Cidara Therapeutics, an antifungal company he helped found in 2012. In 2004, Dr. Judice co-founded Achaogen, Inc. (Nasdaq: AKAO), where, as the first employee, he was the chief scientific officer and chief executive officer. During his seven-year tenure at Achaogen, he oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, Dr. Judice served as the vice president of chemistry at Theravance, where he led the discovery of Vibativ (televancin).
Dr. Judice received his Ph.D. in organic chemistry from the University of California Los Angeles and did his postdoctoral fellowship at the University of California Berkeley. He received his Bachelor of Science in chemistry from Texas A&M University. Dr. Judice is also a Henry Crown Fellow at the Aspen Institute.
Phil Patten, PhD
Founder & Chief Scientific Officer
Dr. Patten joined DiCE Molecules as chief scientific officer in May 2014. Prior to DiCE Molecules, Dr. Patten served at Pioneer HiBred, where he was a DuPont Fellow, research director and led a team of 90 scientists doing directed evolution of proteins and large-scale synthetic biology in the agricultural space. Prior to Pioneer HiBred, Dr. Patten served as senior vice president of biology at Achaogen, where he led the DTRA-funded LpxC program to the discovery of ACHN-975, a small molecule now in Phase 1b with several backup clinical compounds. In addition, he also served as vice president of technology at Maxygen, a pioneer in the field of directed protein evolution via gene shuffling. While at Maxygen, he led the team that produced an improved gene shuffled interferon alpha that entered clinical trials. He is also a named inventor on an evolved herbicide tolerance gene (GAT) that is in late-stage commercial development.
Dr. Patten has been actively involved in the practice of directed evolution since the inception of the field in the early 1980s and he holds more than 80 granted patents in this field. He received his Ph.D. in biology from Stanford University and conducted his postdoctorate education in chemistry at the University of California Berkeley. He received his Bachelor of Science degree in biology from CalTech.
John Jacobsen, PhD
Vice President, Chemistry
Dr. Jacobsen joined DiCE Molecules in November 2015 as vice president of chemistry where he is responsible for the design, development and execution of on-DNA chemistry to build and evaluate chemical libraries. Prior to DiCE Molecules, Dr. Jacobsen was at Theravance Biopharma (formerly Theravance, Inc.) for 18 years, most recently serving as senior director of medicinal chemistry. At Theravance, Dr. Jacobsen led three research programs in respiratory disease and helped transition six compounds into early development. As a member of the Theravance-GlaxoSmithKline Joint Project Committee (JPC), he helped advance collaboration assets through clinical trials to FDA approvals of Breo® and Anoro®. Within the medicinal chemistry department, he had line-management responsibility for as many as three medicinal chemistry teams, as well as the high-throughput purification group.
Dr. Jacobsen holds an A.B. in Chemistry from Harvard College and a Ph.D. in Organic Chemistry from the University of California, Berkeley.
Chief Financial Officer
Mr. Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, Mr. Robertson served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit’s crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, Mr. Robertson was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and previous to that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners. He received a Bachelor of Science in Business Administration from the University of Southern California and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
Vice President, Medicinal Chemistry
Paul joined DiCE Molecules in October 2018 as Vice President of Medicinal Chemistry in the Early Development group. He has over 25 years of medicinal chemistry experience in roles of increasing leadership and has successfully overseen the chemistry and early CMC activities for multiple research programs. Most recently, Paul was at ViewPoint Therapeutics where he was the Vice President of Chemistry overseeing the discovery and early development of small molecule correctors of misfolded proteins. Prior to ViewPoint Therapeutics, Paul was at Theravance Biopharma as a Senior Director of Chemistry where he was involved in the identification of over 7 differentiated clinical candidates across multiple indications, target classes, and routes of administration including Vibativ® (telavancin), Velusetrag (TD-5108), Cefilavancin (TD-1792), and TD-8236 a novel, inhaled pan-JAK inhibitor.
Prior to Theravance BioPharma, Paul was a chemist at Arris Pharmaceuticals and Syntex Research. Paul holds a B.S. in Chemistry from the University of California, Santa Barbara.
Senior Director, Clinical Pharmacology and Drug Metabolism and Pharmacokinetics
Ms. Seroogy joined DiCE Molecules in August 2018 as Senior Director of clinical pharmacology and DMPK where she is responsible for lead selection and optimization of compounds from research through early development. Prior to DiCE Molecules, Ms. Seroogy was at Achaogen for 6 years contributing to the DMPK and clinical pharmacology functions which advanced ZEMDRI™ (plazomicin), a gram-positive antibiotic, and its complementary diagnostic immunoassay through clinical trials and FDA approval.
Ms. Seroogy spent 6 years as a Director of Research at PharmacoFore heading the analytical, bioanalytical and DMPK functions in the field of pain and anesthesia. The team advanced 5 programs from discovery into development with multiple programs successfully completing human Phase 1 clinical studies. Ms. Seroogy spent 8 years at Theravance. where she contributed to progressing VIBATIV® (telavancin), a gram-negative antibiotic, from discovery through Phase 3 clinical development. Prior to Theravance, Ms. Seroogy was in the bioanalytical and pharmacokinetic department at COR Therapeutics where she focused on cardiovascular drugs and contributed to the development of INTEGRILIN® (eptifibatide). Ms. Seroogy holds a B.S. in Zoology from Arizona State University.
Qifeng Xue, PhD
Director, Analytical Chemistry
Dr. Xue joined DiCE Molecules in 2017 as Sr. Director of Analytical Chemistry. In this role, Dr. Xue’s group provides analytical support and expertise to enable all aspects of the DiCE Molecules platform, including characterization of DNA conjugates, protein target evaluation, and development of Routing technology, as well as traditional small molecule analytical characterization.
Prior to joining DiCE, Dr. Xue worked at Theravance Biopharma for over 15 years, most recently serving as Director of Analytical Development. At Theravance, Dr. Xue initially led the Research Analytical group (including High- throughput Purification) to support Drug Discovery before transitioning to Development. In Development, Dr. Xue supported CMC, impurity isolation and characterization and associated Regulatory filings at all stages of Clinical Development. Dr. Xue led development of an industrial scale purification process for manufacturing telavancin (VIBATIV®) drug substance. Prior to joining Theravance, Dr. Xue led assay development team at ACALRA BioSciences, Inc. to develop assays for HTS with an integrated micro-fluidic Lab-on-a-Chip platform.
Dr. Xue holds a B.S. in Chemistry from Shandong University, M.E. from Beijing General Research Institute of Nonferrous Metals, China and a Ph.D. in Analytical Chemistry from the Iowa State University.
Director, Medicinal Chemistry
Bruce Clapham joined DiCE Molecules in October 2017 as Director of Medicinal Chemistry to lead external chemistry efforts and partnered Medicinal Chemistry programs.
Prior to DiCE, Bruce served in various roles in large and small companies as well as in academia. Most recently, Bruce was the Director and Head of Medicinal Chemistry of Reset Therapeutics, a circadian-rhythm drug discovery company. Before joining Reset, Bruce was at Abbott/AbbVie for 11 years where he worked in the High-Throughput Organic Synthesis, Early Discovery (Target validation), Hit-to-Lead and Centralized Lead Optimization groups. Prior to entering the industry, Bruce served as Assistant Professor at The Scripps Research Institute (TSRI) where he conceived and led a multiyear collaboration with Novartis to provide novel synthetic chemistry methodology for their compound screening file efforts.
Bruce completed his postdoctoral training at the TSRI under the mentorship of Prof. Kim Janda. He earned his PhD in Combinatorial Chemistry under the supervision of Dr. Andy Sutherland at Nottingham Trent University, UK. During his career, Bruce has co-authored over 40 papers and patent applications across a broad range of chemical technologies and drug discovery programs.
Dr. Prince joined DiCE Molecules in August 2014 and serves as our Assistant Director of both Informatics and Molecular Biology where she oversees DNA production and downstream sequencing, data processing, and analysis of results. Upon first joining, she worked as a laboratory scientist to develop and improve our core technology.
Prior to DiCE Molecules, Dr. Prince was a postdoctoral associate at University of California Berkeley and the University of California San Francisco working in the field of synthetic biology on engineering genetic tools and proteins. She received her Ph.D. in biological engineering from the Massachusetts Institute of Technology where she studied mammalian cell signaling pathways for her doctoral thesis. In addition to holding a M.S. degree in mechanical engineering from the Massachusetts Institute of Technology, she also has a B.S. degree in mechanical engineering from the University of Arkansas.
Nick Shah, PhD
Head of Assay Science
Nick joined DiCE Molecules as the Head of Assay Science in 2018 and is working with the team to leverage chemical evolution in small molecule drug discovery. Prior to DiCE, he was a member of the FLX Bio team from the company’s inception in 2015. Before FLX, Nick was a very early member of the team at Flexus Biosciences and helped discover a cancer immunotherapy molecule that resulted in an acquisition and is currently in Phase II clinical trials (BMS-986205). Nick has been deeply involved in assay development for drug discovery while leading project teams and managing multiple large-scale screening campaigns.
Nick completed his doctoral work at the University of Toronto, studying the molecular structure and mechanism of an enzyme implicated in cancer. He completed a postdoctoral fellowship at Stanford University working with Bill Weis and Dan Herschlag to understand the enzymatic mechanism of a complex motor protein involved in neurotransmission.
Richard Scheller, PhD
Chairman of the Board
Prior to becoming Chairman of the Board at DiCE Molecules in late 2015, Dr. Scheller had joined 23andMe in January 2015 as Chief Scientific Officer and Head of Therapeutic Development. There, he is responsible for translating genetic information into new therapies.
Hired in 2001 as Senior Vice President of Research and member of the Genentech Executive Committee, from 2009 through 2014, he was Executive Vice President and Head of Genentech Research and Early Development, and a member of the Roche Executive Committee. Dr. Scheller received his Bachelor of Science in biochemistry in 1975 from the University of Wisconsin–Madison and his doctorate in chemistry in 1980 from Caltech. After postdoctoral fellowships at Caltech and Columbia, Dr. Scheller joined the Stanford faculty from 1982 until 2001. An investigator with the Howard Hughes Medical Institute from 1994 to 2001, Dr. Scheller has been an adjunct professor at UC San Francisco since 2004. In 2014, he was named a trustee of Caltech.
Dr. Scheller’s research elucidating molecular mechanisms governing neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology. He is a Fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences and the National Academy of Medicine.
John Bedbrook, PhD
Founder & Member of the Board
Dr. Bedbrook is a founder and Member of the DiCE Molecules Board of Directors. Dr. Bedbrook also serves as vice president of research and development, DuPont Agriculture & Nutrition of EI DuPont De Nemours & Co. Dr. Bedbrook joined DuPont in July 2004 through the acquisition of Verdia Inc. by Pioneer. He was chief executive officer and director of Verdia Inc. and its president from March 2002 to July 2004. He joined Maxygen Inc. as president of Agriculture in November 1999. Before joining Maxygen, Dr. Bedbrook served as chief executive officer of Plant Science Ventures and was chief technology officer at SAVIA from February 1998 to October 1999. Before joining SAVIA, Dr. Bedbrook held several senior management positions, including executive vice president of research and development and co-president at DNA Plant Technology Corp. from 1988 to 1997 and also served as director, science. He was founder and served as vice president of research at Advanced Genetic Sciences Inc.
Dr. Bedbrook earned his Ph.D. in molecular biology from the University of Auckland New Zealand. He was a Fulbright Scholar to Harvard Medical School and held a Jane Coffin Childs Fellowship to Harvard University. He was also a Cabot Fellow at Harvard University and an EMBO Fellow to the Plant Breeding Institute in Cambridge, England.
Pehr Harbury, PhD
Founder, Member of the Board & Chairman - Scientific Advisory Board
Dr. Harbury holds the position of Associate Professor of Biochemistry at the Stanford School of Medicine. He is a pioneer in the field of DNA-encoded organic synthesis and was honored with a prestigious MacArthur genius award for his work in this field. He is a recipient of the ASBMB Young Investigator Award for outstanding contributions in biochemistry and molecular biology, and an NIH Director’s Pioneer Award. His laboratories at Stanford have produced the prototypical DiCE Works instrumentation and protocols. Dr. Harbury is a Founder, Member of the Board, and Chairman – Scientific Advisory Board.
Dr. Harbury received his Ph.D. in chemistry and chemical biology from Harvard University. He also conducted his postdoctoral fellowship at the University of California Berkeley.
Stephen Zachary, PhD
Stephen Zachary is a Principal at Sands Capital Ventures, a venture capital firm based in the Washington DC area. At Sands Capital, Stephen leads private life sciences investments in therapeutic, diagnostic, and life sciences tools businesses. Prior to joining Sands Capital, Stephen received his PhD in neuroscience from Johns Hopkins School of Medicine. Stephen served as Director of Business Development and Research Analytics at Agilis Biotherapeutics, a gene therapy company focused on rare neurological diseases, and is a Kauffman Fellow (Class 23).
Michael P. Rubin, MD, PhD
Michael P. Rubin, M.D., Ph.D. is the founder and CEO of Northpond Ventures, a formative stage venture-capital fund dedicated to science and technology. Dr. Rubin’s active directorships include Mitra Biotech, Selux Diagnostics, NanoView Biosciences, GALT, and DiCE Molecules.
Dr. Rubin was previously co-founder and managing partner of Sands Capital Ventures, a global cross industry venture capital business, and affiliate of Sands Capital Management. Under Dr. Rubin’s leadership, SCV invested in dozens of leading startups, resulting in numerous successful businesses and exits, including DocuSign (IPO), Mulesoft (IPO; sale to Salesforce), AppDynamics (sale to Cisco), Dova (IPO), Paydiant (sale to PayPal), Quad Technologies (sale to Biotechne), Firefly Bioworks (sale to Abcam), and Agilis (Sale to PTC Therapeutics).
Dr. Rubin became a board certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Dr. Rubin has led multiple IRB-approved research groups, published numerous papers in refereed journals, written chapters in leading texts, conducted clinical trials on leading commercial molecules, received NIH funding for novel research, attained industry sponsored funding for original biotherapeutic investigations, presented studies at large international forums, and conducted basic science research in molecular genetics at Harvard’s Ocular Genetics Institute. Dr. Rubin also holds an MBA from The University of Massachusetts Amherst, is a CFA charterholder, earned his medical doctorate at The University of Chicago, and holds a BS in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker.